A decision-making tool for first-line treatment in advanced non-small-cell lung cancer based on plasma proteome biomarkers

被引：0
|
作者：
Sela, Itamar
Christopoulos, Petros
Puzanov, Igor
Bar, Jair
Zer, Alona
Moskovitz, Mor
Reinmuth, Niels
Lotem, Michal
Katzenelson, Rivka
Agbarya, Abed
Farrugia, David
Price, Gillian
Cheley, Helen
Abu-Amana, Mahmud
McGregor, Kimberly
Lou, Yanyan
Leibowitz, Raya
Dicker, Adam P.
Carbone, David Paul
Gandara, David R.
机构：
[1] OncoHost LTD, Binyamina, Israel
[2] Heidelberg Univ Hosp, Heidelberg, Germany
[3] Roswell Pk Canc Inst, Buffalo, NY USA
[4] Sheba Med Ctr, Ramat Gan, Israel
[5] Rambam Hlth, Haifa, Israel
[6] Davidoff Canc Ctr, Rabin Med Ctr, Beilinson Campus, Petah Tiqwa, Israel
[7] Asklepios Clin Munich Gauting, Thorac Oncol, Gauting, Germany
[8] Hadassah Med Ctr, Jerusalem, Israel
[9] Kaplan Med Ctr, Dept Oncol, Rehovot, Israel
[10] Bnei Tzion Hosp, Haifa, Israel
[11] Gloucestershire Oncol Ctr, Cheltenham, England
[12] NHS Grampian, Aberdeen, Scotland
[13] Swansea Bay UHB, Swansea Bay, Wales
[14] Haemek Med Ctr, Afula, Israel
[15] OncoCyte, Cambridge, MA USA
[16] Mayo Clin, Jacksonville, FL USA
[17] Shamir Med Ctr, Beer Yaagov, Israel
[18] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA
[19] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA
[20] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9122
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
    Lisberg, Aaron
    Garon, Edward Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07) : 529 - +
  • [42] First-line management of advanced non-small-cell lung cancer: can we do better?
    Chouaid, Christos
    Monnet, Isabelle
    Auliac, Jean-Bernard
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1643 - 1648
  • [43] Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
    Argiris, A
    Mittal, N
    LUNG CANCER, 2004, 43 (03) : 317 - 322
  • [44] Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer A Brazilian Center Experience
    Fontes Jardim, Denis Leonardo
    Gagliato, Debora de Melo
    Ribeiro, Karina Braga
    Shimada, Andrea Kazumi
    Katz, Artur
    DRUGS IN R&D, 2012, 12 (04) : 207 - 216
  • [45] FIRST-LINE ERLOTINIB IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Merimsky, O.
    Cheng, A. C.
    Reck, M.
    Au, S. K.
    von Pawel, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 101 - 102
  • [46] Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer
    Decatris, Marios P.
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2016, 12 (15) : 1805 - 1822
  • [47] First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era
    Capelletto, Enrica
    Novello, Silvia
    Scagliotti, Giorgio V.
    FUTURE ONCOLOGY, 2014, 10 (06) : 1081 - 1093
  • [48] Achieving Response and Improving Outcomes of First-line Therapy for Advanced Non-small-cell Lung Cancer
    Loh, K. K.
    HONG KONG JOURNAL OF RADIOLOGY, 2013, 16 (04): : S23 - S28
  • [49] Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: A Brazilian center experience
    Jardim D.L.F.
    De Melo Gagliato D.
    Ribeiro K.B.
    Shimada A.K.
    Katz A.
    Drugs in R&D, 2012, 12 (4) : 207 - 216
  • [50] Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
    Shen, Yan-Wei
    Zhang, Xiao-Man
    Li, Shu-Ting
    Lv, Meng
    Yang, Jiao
    Wang, Fan
    Chen, Zhe-Ling
    Wang, Bi-Yuan
    Li, Pan
    Chen, Ling
    Yang, Jin
    ONCOTARGETS AND THERAPY, 2016, 9 : 929 - 935
12345